Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance - Wikidata - wikimedia - TriplyDB

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

http://www.wikidata.org/entity/Q30500080

about

Homeostatic Signaling by Cell-Cell Junctions and Its Dysregulation during Cancer Progression Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Using circulating tumor cells to inform on prostate cancer biology and clinical utility Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies Ell3 enhances differentiation of mouse embryonic stem cells by regulating epithelial-mesenchymal transition and apoptosis Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer Aggressive variants of castration-resistant prostate cancer Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Epithelial-mesenchymal transition in prostate cancer: an overview.Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.The role of epithelial plasticity in prostate cancer dissemination and treatment resistance SOX4 mediates TGF-β-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition.The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers.N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines A comprehensive analysis of adiponectin QTLs using SNP association, SNP cis-effects on peripheral blood gene expression and gene expression correlation identified novel metabolic syndrome (MetS) genes with potential role in carcinogenesis and system Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.Targeting tumor cell motility to prevent metastasis.Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation IGFBP-3 is a metastasis suppression gene in prostate cancer Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer.AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer.Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis.Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.Prostate cancer stem cells: The case for model systems Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.

P2860

Q26768428-EB9CF7B4-E9DA-44DE-B214-86559A076975 Q26797063-F9EE8E7E-AFA4-44E3-AD36-965C46214D4F Q26858922-B94720FD-1595-468C-BF86-18A11F581A96 Q27024775-A34F1F76-B95E-4DE1-8E1B-8323A7BB4C3C Q27317689-0DCC3F53-1A30-439B-86E6-7BC8999150B1 Q28075965-64F2F766-ACCE-4E3E-B32A-E804DAA7BD13 Q28083261-B1E78FD1-BB0E-41B3-A232-270D4BC4BCA1 Q28237085-F74EC02F-A6CE-4227-8506-F38EF2095661 Q28590241-6D105A31-771E-4EE1-A2F5-3A7A8AA28F60 Q33351622-7F7842A2-9884-49B2-9AAA-37A693AFA2D1 Q33636318-4A6FFF9D-497D-472B-94E0-9AD26279CBE6 Q33693256-A433D194-2275-4AF4-A8C4-60848EF591DF Q33775723-FF1D3AF7-F9A9-4F38-9353-1F28790B94D4 Q33798864-D4EB0CB3-5AA0-4A1C-98D0-41B3C54C034C Q34390313-99C3BA29-D8A3-4805-BDE3-24750D1F564E Q34397291-DDA06D32-04F0-4AE6-8B28-DB1823CED2BE Q34425201-48CB5C12-7308-460B-9401-05712442E099 Q34505037-2DDAD09F-6C9A-4F50-ACC2-A38A0E722DDB Q34542397-7E1728A9-DAA9-4D2B-8F18-7B907271DE40 Q34559250-E6954BB2-CFC8-4018-AA63-A7A2C6F79D1A Q34631703-F39F4673-9D75-4DD8-A4FF-F607F87B6707 Q34694696-738609EF-B5F2-4BF2-B548-DDFEBFA542F1 Q34713218-26524458-56E8-4221-88F7-4640F237C855 Q34988368-73D7E895-FAE0-4172-B00C-59CFDC4B26A3 Q35095152-EDCE0F48-11FB-4ABA-A777-B54FD89B3664 Q35111968-A6DF032D-D232-4791-999C-95EDF1CFEF1F Q35141734-FE3E2F3A-412E-4790-AE30-061F93C464EC Q35168294-1BF49E16-B77F-4BC2-8D8F-61A524D4F842 Q35169094-AFE1C279-7BFD-4FFE-A424-E4C26E1B8365 Q35214708-EB0233D1-3F50-4D81-90BA-9D7C4F3C124D Q35224818-393F3291-5DBD-46CD-B277-5736C7BBC364 Q35474421-1BC23423-214A-4CC8-9368-91FF0C1A861A Q35600629-E7257A99-894D-4D9D-9BC4-0EF2113E98D1 Q35611451-0D446D6F-B9FB-4CF2-A652-28E2DF83469F Q35631433-015FD291-E313-4171-9C03-BEAE6A69D293 Q35806990-DD98580A-1C29-49F3-9DD8-438D26BEA4A6 Q35812184-2FEF23B6-7F28-4D51-BC87-8901088A33BF Q35871737-062E8D7C-E341-4561-A569-2595E6EC4D70 Q35890704-E3685379-A802-43B9-914E-963015F9A811 Q35922320-45547921-06F0-4B8F-9567-32BECAA173E9

P2860

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

http://www.wikidata.org/entity/Q30500080

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Monoclonal antibody targeting ...... asis and castration resistance

@ast

Monoclonal antibody targeting ...... asis and castration resistance

@en

type

label

Monoclonal antibody targeting ...... asis and castration resistance

@ast

Monoclonal antibody targeting ...... asis and castration resistance

@en

prefLabel

Monoclonal antibody targeting ...... asis and castration resistance

@ast

Monoclonal antibody targeting ...... asis and castration resistance

@en

P1433

Q30500080-B7E808EF-BDC4-40D0-AF37-3964F3E188C0

P1476

Q30500080-2148717C-6E1E-44F7-A964-29F3AE4820A8

P2093

Q30500080-169AE0E5-7858-45FB-BB30-2FAB225F72D9

Q30500080-1A1BEBC8-9EE8-4893-9176-682AD0EE1065

Q30500080-44320119-0466-4AB2-9F5A-E861405FF4AD

Q30500080-63C7DDFF-40C7-4ACA-81A5-B74F656BFF1F

Q30500080-6F91DAA2-1723-46E7-94A7-A18AAE033041

Q30500080-815531F4-A8C6-4C06-AA61-1F0D406BEC0E

Q30500080-8DCDED87-ED86-4A73-BE09-EBDCF360C462

Q30500080-8DF4BFCD-7A43-4F91-9CE3-481A26DCC8F9

Q30500080-9D20C430-313B-4380-8ED3-011E072A2B1C

Q30500080-A46973D7-1FBD-47A7-9BA0-4960F112CF00

P2860

Q30500080-0D006A61-4A2C-4472-BA22-ECFB8C8C85EC

Q30500080-101F8AFD-E075-46E1-8C55-7B6E40659F3C

Q30500080-1F6EF764-4BB7-4254-946D-AF7C36D55C0C

Q30500080-2F6AAA71-5F50-4E80-AD44-E45872AA888E

Q30500080-44675CE9-6757-4A38-B163-5D4F66135960

Q30500080-5CBB38C0-21E0-410C-A1F0-47BB4CEA490C

Q30500080-805F8651-D863-4530-8694-5E3F03754A2D

Q30500080-877F2F3F-6599-487F-89E6-D5108DB41CF3

Q30500080-8B4BF6C7-E8DF-4369-BB9B-ADC6C0E0A0B6

Q30500080-932FA769-D215-4AB1-B6D5-CED4E68020F8

P2888

Q30500080-24E9E3B4-09C0-4683-BFAC-D733A06281D9

P304

Q30500080-0092C3E7-1109-49DC-A3AF-C1219F536FF2

P31

Q30500080-4461F96E-858F-4282-AB7C-8FFDE13F6FEE

P356

Q30500080-26602E5F-F148-408B-86F1-30D9FD4ACEC0

P407

Q30500080-5893ED08-2301-4F94-9422-868C31F06FBD

P433

Q30500080-8F055B6E-CFF9-42CA-9334-E8628348D14F

P478

Q30500080-DBC0637D-0353-4572-A1A0-B442AE357E14

P577

Q30500080-2DC1CA02-D852-4327-8F89-8897C250E24C

P5875

Q30500080-36292AC6-E532-4776-BB0B-C62181B3D6AD

P698

Q30500080-EE2C84C5-F304-4067-8BBC-1277A12A174E

P921

Q30500080-3B7B297A-4CD5-405E-BD20-DB676D99CDA4

P932

Q30500080-151963C6-363B-4226-BC12-6BBBEECDF89E

P356

P1433

Nature Medicine

P1476

Monoclonal antibody targeting ...... asis and castration resistance

@en

P2093

Chau P Tran

http://www.w3.org/2001/XMLSchema#string

Evelyn Kono

http://www.w3.org/2001/XMLSchema#string

Hideyo Miyazaki

http://www.w3.org/2001/XMLSchema#string

Hiroshi Tanaka

http://www.w3.org/2001/XMLSchema#string

Jaibin An

http://www.w3.org/2001/XMLSchema#string

Jiaoti Huang

http://www.w3.org/2001/XMLSchema#string

Joyce Yamashiro

http://www.w3.org/2001/XMLSchema#string

Ladan Fazli

http://www.w3.org/2001/XMLSchema#string

Martin Gleave

http://www.w3.org/2001/XMLSchema#string

Matthew B Rettig

http://www.w3.org/2001/XMLSchema#string

P2860

The epithelial-mesenchymal transition generates cells with properties of stem cells

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Signed weighted gene co-expression network analysis of transcriptional regulation in murine embryonic stem cells.

The biology of hormone refractory prostate cancer. Why does it develop?

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Reg IV: a promising marker of hormone refractory metastatic prostate cancer.

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Androgen receptor involvement in the progression of prostate cancer.

P2888

P304

1414-1420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2236

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47701339

http://www.w3.org/2001/XMLSchema#string

P698

21057494

http://www.w3.org/2001/XMLSchema#string

P921

P932

3088104

http://www.w3.org/2001/XMLSchema#string